男性性腺機能低下症市場：治療タイプ（テストステロン補充療法、ゴナドトロピン放出ホルモン療法）、ドラッグデリバリー（局所ゲル、注射剤、経皮パッチ、その他）、アプリケーション（カルマン症候群、クラインフェルターズ症候群、下垂体障害、その他）、地域別 2023-2028

Male Hypogonadism Market by Therapy Type (Testosterone Replacement Therapy, Gonadotropin-Releasing Hormones Therapy), Drug Delivery (Topical Gels, Injectables, Transdermal Patches, and Others), Application (Kallmann Syndrome, Klinefelters Syndrome, Pituitary Disorders, and Others), and Region 2023-2028

市場の概要世界の男性性腺機能低下症の市場規模は、2022年に35億米ドルに達しました。今後、IMARC Groupは、2023年から2028年の間に5.20％の成長率（CAGR）を示し、2028年までに49億米ドルに達すると予測して... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
IMARC Services Private Limited. アイマークサービス	2023年3月18日	US$2,499 シングルユーザライセンスライセンス・価格情報注文方法はこちら	143	英語

サマリー

市場の概要

世界の男性性腺機能低下症の市場規模は、2022年に35億米ドルに達しました。今後、IMARC Groupは、2023年から2028年の間に5.20％の成長率（CAGR）を示し、2028年までに49億米ドルに達すると予測しています。男性におけるテストステロン欠乏症の有病率の大幅な上昇、患者集団における男性性腺機能低下症治療の選択肢に対する意識の高まり、健康意識の高まりなどが、市場を牽引する主な要因の一部となっています。

男性性腺機能低下症とは、精巣から十分なテストステロンが分泌されず、筋肉が成長しない、髪が伸びない、乳房が発達しない、また、声が深くならないなどの症状が現れる医学的疾患です。この病状は、男性におけるテストステロンまたは精子の生成の欠如を特徴とします。精巣（原発性性腺機能低下症）または視床下部-下垂体軸（二次性腺機能低下症）に関連する障害によって引き起こされます。視床下部や下垂体に影響を及ぼす精巣の問題や障害に起因するため、性腺機能低下症になると、さまざまな臓器の機能障害や生活の質の低下に悩まされることになります。男性の性腺機能低下症は、遺伝的なものと後天的なものがあり、ホルモンバランスの乱れや薬物、加齢などによって引き起こされます。いくつかの先天性酵素異常は、体全体で異なる程度のアンドロゲン抵抗性を引き起こす原因となっています。性腺機能低下症は、60歳以上の男性に最も多くみられ、それに応じて症状や適応も異なってきます。

男性性腺機能低下症の市場動向：

世界市場は、主に男性におけるテストステロン欠乏症の有病率の大幅な上昇と、不妊症の増加によって牽引されています。この背景には、肥満や糖尿病などの慢性的な生活習慣病の増加があります。また、男性性腺機能低下症を発症しやすい老年人口が増加していることも、市場を活性化させています。さらに、男性性腺機能低下症の治療法に対する患者層の意識の高まりも、大きな成長促進要因として作用しています。いくつかの国の政府機関は、テストステロン補充療法（TST）を含む性腺機能低下症治療法の認知を促進しています。しかし、テストステロンホルモンの外部注射に関連する重篤な副作用が、男性性腺機能低下症市場の重大な成長抑制要因として作用しています。逆に、臨床試験の増加や新たな治療法の出現により、予測期間中に新たな男性性腺機能低下症市場の成長機会が創出されると期待されています。これとは別に、世界レベルでの医療インフラ整備における継続的な技術進歩が、市場に明るい展望を生み出しています。その他、急速な都市化、健康意識の高まり、高額な医療費、大規模な研究開発（R&D）活動などが、市場に寄与する要因として挙げられます。

主要な市場セグメント：

IMARC Groupは、世界の男性性腺機能低下症市場の各セグメントにおける主要動向の分析と、2023年から2028年までの世界、地域、国レベルでの予測を提供します。当レポートでは、市場を治療タイプ、ドラッグデリバリー、アプリケーションに基づき分類しています。

治療タイプ別インサイト

男性ホルモン補充療法（Testosterone Replacement Therapy
ゴナドトロピン放出ホルモン療法

本レポートでは、男性性腺機能低下症市場を治療法の種類に基づいて詳細に分類・分析しています。これには、テストステロン補充療法とゴナドトロピン放出ホルモン療法が含まれます。それによると、テストステロン補充療法が最も大きなセグメントを占めています。

ドラッグデリバリーインサイト

トピカルジェル
インジェクタブル
経皮吸収型テープ製剤
その他

本レポートでは、ドラッグデリバリーに基づく男性性腺機能低下症市場を詳細に分解・分析しています。これには、局所ゲル、注射剤、経皮吸収パッチ、その他が含まれます。それによると、局所用ゲルは最大のセグメントを占めています。

アプリケーションインサイト

カルマンしょうこうぐん
クラインフェルターズ症候群
下垂体疾患
その他

また、男性性腺機能低下症市場の用途に基づく詳細な分解・分析も報告されています。これには、カルマン症候群、クラインフェルターズ症候群、下垂体障害、その他が含まれます。

地域別インサイト

北アメリカ

ユーエスエー
カナダ

アジア太平洋

中国
日本
インド
南朝鮮
オーストラリア
インドネシア
その他

ヨーロッパ

ドイツ
フランス
イギリス
イタリア
スペイン
ロシア
その他

ラテンアメリカ

ブラジル
メキシコ
その他

中近東・アフリカ

また、北米（米国、カナダ）、アジア太平洋（中国、日本、インド、韓国、オーストラリア、インドネシア、その他）、欧州（ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他）、中南米（ブラジル、メキシコ、その他）、中東・アフリカを含むすべての主要地域市場について包括的に分析を行っています。それによると、男性性腺機能低下症の市場規模は、北米が最大でした。北米の男性性腺機能低下症市場を牽引する要因としては、老年人口の増加、座りがちなライフスタイルや関連疾患の有病率の上昇、臨床試験数の増加、新しい治療オプションの出現などが挙げられます。

競合の状況：

また、世界の男性性腺機能低下症市場における競争環境についても包括的に分析しています。また、すべての主要企業の詳細なプロファイルも提供しています。対象となる企業には、AbbVie Inc、Endo International Plc、Ferring Holding S.A、Grünenthal GmbH、Lilly USA, LLC (Eli Lilly and Company)、Pfizer Inc、Sun Pharmaceutical Industries Limited、Teva Pharmaceutical Industries Ltd などがあります。なお、これは企業の一部のリストであり、完全なリストは報告書で提供されています。

本レポートで回答した主な質問

世界の男性性腺機能低下症市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
世界の男性性腺機能低下症市場における促進要因、阻害要因、機会は何か？
主要な地域市場とは？
最も魅力的な男性性腺機能低下症市場を代表する国はどこか？
治療法の種類に基づく市場の内訳は？
薬物送達に基づく市場の内訳は？
アプリケーションに基づく市場の内訳は？
世界の男性性腺機能低下症市場の競争構造は？
世界の男性性腺機能低下症市場における主要プレイヤー/企業は？

ページTOPに戻る

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Male Hypogonadism Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Therapy Type
6.1 Testosterone Replacement Therapy
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Gonadotropin-Releasing Hormones Therapy
6.2.1 Market Trends
6.2.3 Market Forecast
7 Market Breakup by Drug Delivery
7.1 Topical Gels
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Injectables
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Transdermal Patches
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Application
8.1 Kallmann Syndrome
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Klinefelters Syndrome
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Pituitary Disorders
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AbbVie Inc
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Endo International Plc
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Ferring Holding S.A
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Grünenthal GmbH
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 SWOT Analysis
14.3.5 Lilly USA, LLC (Eli Lilly and Company)
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Pfizer Inc
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Sun Pharmaceutical Industries Limited
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Teva Pharmaceutical Industries Ltd
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

Figure 1: Global: Male Hypogonadism Market: Major Drivers and Challenges
Figure 2: Global: Male Hypogonadism Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Male Hypogonadism Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Male Hypogonadism Market: Breakup by Therapy Type (in %), 2022
Figure 5: Global: Male Hypogonadism Market: Breakup by Drug Delivery (in %), 2022
Figure 6: Global: Male Hypogonadism Market: Breakup by Application (in %), 2022
Figure 7: Global: Male Hypogonadism Market: Breakup by Region (in %), 2022
Figure 8: Global: Male Hypogonadism (Testosterone Replacement Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Male Hypogonadism (Testosterone Replacement Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Male Hypogonadism (Gonadotropin-Releasing Hormones Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Male Hypogonadism (Gonadotropin-Releasing Hormones Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Male Hypogonadism (Topical Gels) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Male Hypogonadism (Topical Gels) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Male Hypogonadism (Injectables) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Male Hypogonadism (Injectables) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Male Hypogonadism (Transdermal Patches) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Male Hypogonadism (Transdermal Patches) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Male Hypogonadism (Other Drug Deliveries) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Male Hypogonadism (Other Drug Deliveries) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Male Hypogonadism (Kallmann Syndrome) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Male Hypogonadism (Kallmann Syndrome) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Male Hypogonadism (Klinefelters Syndrome) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Male Hypogonadism (Klinefelters Syndrome) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: Male Hypogonadism (Pituitary Disorders) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: Male Hypogonadism (Pituitary Disorders) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: Global: Male Hypogonadism (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: Global: Male Hypogonadism (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: North America: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: North America: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: United States: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: United States: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: Canada: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: Canada: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: Asia-Pacific: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: Asia-Pacific: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: China: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: China: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: Japan: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: Japan: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: India: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: India: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: South Korea: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: South Korea: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: Australia: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: Australia: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Indonesia: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Indonesia: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Others: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Others: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: Europe: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: Europe: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: Germany: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: Germany: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: France: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: France: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: United Kingdom: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: United Kingdom: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: Italy: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: Italy: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Spain: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Spain: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Russia: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Russia: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Others: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Others: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Latin America: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Latin America: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Brazil: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Brazil: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Mexico: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Mexico: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 72: Others: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 73: Others: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 74: Middle East and Africa: Male Hypogonadism Market: Sales Value (in Million US$), 2017 & 2022
Figure 75: Middle East and Africa: Male Hypogonadism Market: Breakup by Country (in %), 2022
Figure 76: Middle East and Africa: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 77: Global: Male Hypogonadism Industry: Drivers, Restraints, and Opportunities
Figure 78: Global: Male Hypogonadism Industry: Value Chain Analysis
Figure 79: Global: Male Hypogonadism Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Male Hypogonadism Market: Key Industry Highlights, 2022 & 2028
Table 2: Global: Male Hypogonadism Market Forecast: Breakup by Therapy Type (in Million US$), 2023-2028
Table 3: Global: Male Hypogonadism Market Forecast: Breakup by Drug Delivery (in Million US$), 2023-2028
Table 4: Global: Male Hypogonadism Market Forecast: Breakup by Application (in Million US$), 2023-2028
Table 5: Global: Male Hypogonadism Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Male Hypogonadism Market: Competitive Structure
Table 7: Global: Male Hypogonadism Market: Key Players

ページTOPに戻る

Table of Contents

Summary

Market Overview:

The global male hypogonadism market size reached US$ 3.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.9 Billion by 2028, exhibiting a growth rate (CAGR) of 5.20% during 2023-2028. A considerable rise in the prevalence of testosterone deficiency in males, the rising awareness of male hypogonadism treatment choices among the patient population, and increasing health consciousness represent some of the key factors driving the market.

Male hypogonadism is a medical condition in which the testes fail to produce enough testosterone, leading to a lack of muscle growth, impaired hair growth, breast development, as well as a lack of deepening of the voice. The medical condition is characterized by a lack of testosterone or spermatozoa production in men. It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism). An individual with hypogonadism may suffer from a variety of organ dysfunctions as well as a reduction in quality of life since it originates from a testicular problem or disorder that affects the hypothalamus and pituitary gland. Hypogonadism in men can be genetic or acquired, caused by hormonal imbalances, medications or aging. Several congenital enzyme abnormalities are responsible for causing different degrees of androgen resistance throughout the body. Hypogonadism is most common in men over the age of 60, and the symptoms and indications of the deficiency vary accordingly.

Male Hypogonadism Market Trends:

The global market is primarily driven by a considerable rise in the prevalence of testosterone deficiency in males, along with the growing infertility rates. This can be attributed to the increasing incidences of chronic lifestyle disorders, including obesity and diabetes. In line with this, the expanding geriatric population that is more susceptible to developing male hypogonadism is also providing an impetus to the market. Moreover, the rising awareness of male hypogonadism treatment choices among the patient population is also acting as a significant growth-inducing factor. Government bodies across several countries are promoting awareness of hypogonadism treatment methods, including testosterone replacement therapy (TST). However, severe adverse reactions associated with external testosterone hormone injections are acting as a significant growth-restraining factor for the male hypogonadism market. Conversely, the increasing number of clinical trials and the emergence of new treatment options are expected to create new male hypogonadism market opportunities for growth during the forecast period. Apart from this, continual technological advancements in the development of medical infrastructure on the global level are creating a positive outlook for the market. Some of the other factors contributing to the market include rapid urbanization, increasing health consciousness, high medical expenditure and extensive research and development (R&D) activities.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global male hypogonadism market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on therapy type, drug delivery and application.

Therapy Type Insights

Testosterone Replacement Therapy
Gonadotropin-Releasing Hormones Therapy

The report has provided a detailed breakup and analysis of the male hypogonadism market based on the therapy type. This includes testosterone replacement therapy and gonadotropin-releasing hormones therapy. According to the report, testosterone replacement therapy represented the largest segment.

Drug Delivery Insights

Topical Gels
Injectables
Transdermal Patches
Others

The report has provided a detailed breakup and analysis of the male hypogonadism market based on the drug delivery. This includes topical gels, injectables, transdermal patches, and others. According to the report, topical gels represented the largest segment.

Application Insights

Kallmann Syndrome
Klinefelters Syndrome
Pituitary Disorders
Others

A detailed breakup and analysis of the male hypogonadism market based on the application has also been provided in the report. This includes Kallmann Syndrome, Klinefelters Syndrome, pituitary disorders, and others.

Regional Insights

North America

United States
Canada

Asia Pacific

China
Japan
India
South Korea
Australia
Indonesia
Others

Europe

Germany
France
United Kingdom
Italy
Spain
Russia
Others

Latin America

Brazil
Mexico
Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for male hypogonadism. Some of the factors driving the North America male hypogonadism market include the growing geriatric population, rising prevalence of sedentary lifestyle and related medical conditions, increasing number of clinical trials, the emergence of new treatment options, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global male hypogonadism market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc, Endo International Plc, Ferring Holding S.A, Grünenthal GmbH, Lilly USA, LLC (Eli Lilly and Company), Pfizer Inc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global male hypogonadism market performed so far and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global male hypogonadism market?
What are the key regional markets?
Which countries represent the most attractive male hypogonadism markets?
What is the breakup of the market based on the therapy type?
What is the breakup of the market based on the drug delivery?
What is the breakup of the market based on the application?
What is the competitive structure of the global male hypogonadism market?
Who are the key players/companies in the global male hypogonadism market?

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

IMARC Services Private Limited.社の医療分野での最新刊レポート

本レポートと同じKEY WORD（drug）の最新刊レポート

よくあるご質問

IMARC Services Private Limited.社はどのような調査会社ですか?

インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療）の最新刊レポート

IMARC Services Private Limited.社の医療分野での最新刊レポート

本レポートと同じKEY WORD（drug）の最新刊レポート

よくあるご質問

IMARC Services Private Limited.社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?